[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362257-105":3,"detail-sidebar-cat-0-en-105":73,"doc-detail-362257-en":122},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":66,"head_meta":68,"extra_data":70,"updated_unix":72},105,"en","prognostic-significance-of-pd-l1pd-1-co-expression-and-cxcr3-driven-inflammatory-signatures-in-egyptian-patients-with-lymphoproliferative-neoplasms","Prognostic significance of PD-L1/PD-1 co-expression and CXCR3-driven inflammatory signatures in Egyptian patients with lymphoproliferative neoplasms","","Lymphoproliferative neoplasms (LPNs) such as chronic lymphocytic leukemia and non-Hodgkin lymphomas show clinical heterogeneity, recurrence, and poor outcomes, yet immune marker-based risk stratification in Egypt remains insufficient. Aiming to evaluate whether PD-L1/PD-1 co-expression with CXCR3, systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI)—including CXCR3 expression on monocyte subsets and lymphocytes—predict prognosis, the case-control study enrolled 90 LPN patients and 90 matched controls. Flow cytometry and inflammatory indices were analyzed alongside remission, relapse, and survival.",{"@graph":14,"@context":65},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognostic-significance-of-pd-l1pd-1-co-expression-and-cxcr3-driven-inflammatory-signatures-in-egyptian-patients-with-lymphoproliferative-neoplasms/362257/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognostic-significance-of-pd-l1pd-1-co-expression-and-cxcr3-driven-inflammatory-signatures-in-egyptian-patients-with-lymphoproliferative-neoplasms/362257.png","ImageObject",300,407,{"name":42,"@type":43},"Genevieve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59],{"name":60,"@type":61,"acceptedAnswer":62},"Which markers showed high accuracy for identifying advanced (stage IV) disease?","Question",{"text":63,"@type":64},"SIRI, PD-L1/CXCR3, and PD-1/CXCR3 demonstrated high accuracy for identifying stage IV disease, and lower baseline levels were associated with superior survival.","Answer","https://schema.org",{"og:url":32,"og:type":67,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":69,"canonical":32},"index,follow",{"doc_id":71,"site_id":7},362257,1790193049,{"code":4,"msg":74,"data":75},"success",[76,80,84,88,93,98,103,107,112,115,118],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":77,"show_sort_weight":78,"slug":79},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":81,"show_sort_weight":82,"slug":83},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Exam",70,"exam",{"id":89,"doc_module":4,"doc_module_name":25,"category_name":90,"show_sort_weight":91,"slug":92},5,"Comic",60,"comic",{"id":94,"doc_module":4,"doc_module_name":25,"category_name":95,"show_sort_weight":96,"slug":97},6,"Technology",50,"technology",{"id":99,"doc_module":4,"doc_module_name":25,"category_name":100,"show_sort_weight":101,"slug":102},7,"Healthcare",40,"healthcare",{"id":104,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":105,"slug":106},8,30,"research-report",{"id":108,"doc_module":4,"doc_module_name":25,"category_name":109,"show_sort_weight":110,"slug":111},9,"Religion & Spirituality",20,"religion-spirituality",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":113,"show_sort_weight":110,"slug":114},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":55,"slug":117},"Lifestyle","lifestyle",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":89,"slug":121},19,"General","general",{"code":4,"msg":74,"data":123},{"doc_id":71,"user_id":124,"nickname":42,"user_avatar":125,"doc_module":4,"category_id":104,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":131,"language":132,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":12,"update_tm":136,"read_time":91,"preview_page_count":33,"preview_urls":137},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","| W | J | C | O | World Journal of\u003Cbr>Clinical Oncology |\n| --- | --- | --- | --- | --- |\n\nSubmit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Clin Oncol 2026 January 24; 17(1): 112801  \nDOI: 10.5306/wjco.v17.i1.112801 ISSN 2218-4333 (online)  \nORIGINAL ARTICLE  \nCase Control Study  \nPrognostic significance of PD-L1/PD-1 co-expression and CXCR3-driven inflammatory signatures in Egyptian patients with lymphoproliferative neoplasms  \nDalia E Sherief, Nahla Nosair, Aya Mohammed Abdelhameed, Emad Sadaka, Amira A A Othman, Rasha Elgamal  \nSpecialty type: Oncology  \nProvenance and peer review:  \nInvited article; Externally peer reviewed.  \nPeer-review model: Single blind  \nPeer-review report’s classification Scientific Quality: Grade B, Grade C  \nNovelty: Grade C, Grade C  \nCreativity or Innovation: Grade C, Grade C  \nScientific Significance: Grade C, Grade C  \nP-Reviewer: Elfishawi S, Associate Professor, Egypt; Hantash NA, MD, Researcher, Jordan  \nReceived: August 6, 2025  \nRevised: September 3, 2025  \nAccepted: November 17, 2025  \nPublished online: January 24, 2026  \nProcessing time: 167 Days and 12.5 Hours  \nDalia E Sherief, Nahla Nosair, Aya Mohammed Abdelhameed, Clinical Pathology, Faculty of Medicine, Kafr Elsheikh University, Kafr Elsheikh 33511, Kafr ash Shaykh, Egypt  \nEmad Sadaka, Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Kafr Elsheikh University, Kafr Elsheikh 33511, Kafr ash Shaykh, Egypt  \nAmira A A Othman, Department of Internal Medicine, Faculty of Medicine, Suez University, Suez 43511, As Suways, Egypt  \nRasha Elgamal, Clinical Pathology, Faculty of Medicine, Suez University, Suez 43511, As Suways, Egypt  \nCorresponding author: Amira A A Othman, MD, PhD, Chief Physician, Professor, Department of Internal Medicine, Faculty of Medicine, Suez University, Cairo-Suez Road, Suez 43511, As Suways, [Egypt.](Egypt. amira.othman@med.suezuni.edu.eg)[ amira.othman@med.suezuni.edu.eg](Egypt. amira.othman@med.suezuni.edu.eg)  \nAbstract  \nBACKGROUND  \nLymphoproliferative neoplasms (LPNs) such as chronic lymphocytic leukemia and non-Hodgkin lymphomas are clinically heterogeneous and frequently associated with recurrence and poor outcomes. Immune checkpoint markers, including programmed death-ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1), as well as C-X-C motif chemokine receptor 3 (CXCR3) and inflammationbased indices [systemic immune-inflammation index (SII) and systemic inflammation response index (SIRI)], have shown promise in risk stratification but remain underexplored in Egyptian populations.  \nAIM  \nTo assess the prognostic value of PD-L1/PD-1 co-expression with CXCR3, SII, SIRI, and CXCR3 expression on monocyte subsets and lymphocytes in Egyptian patients with LPNs.  \nMETHODS  \nA case-control study was conducted at Kafr Elsheikh University Hospitals (January 2024 to January 2025), including 90 patients with LPNs (chronic lymphocytic  \n [https://dx.doi.org/10.5306/wjco.v17.i1.112801](https://dx.doi.org/10.5306/wjco.v17.i1.112801) 1 January 24, 2026  Volume 17  Issue 1   \nSherief DE et al. Egyptian lymphoma: CXCR3 and immune markers  \nleukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma) and 90 matched healthy controls. All participants underwent clinical evaluation, laboratory testing (including complete blood count, Creactive protein, lactate dehydrogenase, and ferritin), and flow cytometry for PD-L1, PD-1, and CXCR3 . Inflammatory indices (SII, SIRI, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and ferritin-to-lymphocyte ratio) were calculated. Clinical outcomes included remission, recurrence, and survival.  \nRESULTS  \nPatients with LPNs had marked hematological and biochemical alterations, including anemia, thrombocytopenia, and reduced neutrophils, with significantly elevated lactate dehydrogenase, C-reactive protein, ferritin, and systemic inflammatory indices (SII, SIRI) . Inflammatory ratios (neutrophi","cbCaigNeH43sjFfU","https://ap.wps.com/l/cbCaigNeH43sjFfU","pdf",2939219,24,"English","# Abstract\n## Background\n## Aim\n## Methods\n## Results\n## Conclusion","[{\"question\":\"Which markers showed high accuracy for identifying advanced (stage IV) disease?\",\"answer\":\"SIRI, PD-L1/CXCR3, and PD-1/CXCR3 demonstrated high accuracy for identifying stage IV disease, and lower baseline levels were associated with superior survival.\"}]","Prognostic significance of PD-L1/PD-1 co-expression and CXCR3-driven inflammatory signatures in Egyptian patients with lymphoproliferative neoplasms | PDF",1790146908,[138,142,146,150],{"page_no":22,"url":139,"width":140,"height":141},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1bee164ad15084a3c574656822d5da01.webp",983,1390,{"page_no":26,"url":143,"width":144,"height":145},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1e6585e004ba1a68ec007bc6015f030f.webp",982,1389,{"page_no":30,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d480b935d011994ae00fc545348f8052.webp",981,1387,{"page_no":33,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04e79bde7695af1a9f63204935ad36f6.webp",980,1386]